CALGARY,
June 19, 2014 /CNW/ - Oncolytics
Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all
nominees listed in the management information circular dated
May 9, 2014 were elected as directors
at its 2014 Annual Meeting of Shareholders, held on Wednesday June 18th, 2014. On a vote
by ballot, the following 10 nominees proposed by management were
elected as Directors of Oncolytics to serve until the Company`s
next Annual Meeting of Shareholders or until their successors are
elected or appointed, with shares represented at the meeting voting
in favour of individual nominees as follows:
Director |
For |
% |
Withheld |
% |
Ger van Amersfoort |
13,138,482 |
93.53% |
909,206 |
6.47% |
Matthew Coffey |
12,772,377 |
90.92% |
1,275,312 |
9.08% |
Jim Dinning |
11,675,341 |
83.11% |
2,372,347 |
16.89% |
Linda Hohol |
12,509,026 |
89.05% |
1,538,662 |
10.95% |
Angela Holtham |
12,520,502 |
89.13% |
1,527,186 |
10.87% |
Ed Levy |
12,369,473 |
88.05% |
1,678,215 |
11.95% |
Mark Lievonen |
11,778,509 |
83.85% |
2,269,179 |
16.15% |
Wayne Pisano |
13,090,751 |
93.19% |
956,937 |
6.81% |
Robert Schultz |
12,849,006 |
91.47% |
1,198,682 |
8.53% |
Brad Thompson |
12,299,004 |
87.55% |
1,748,684 |
12.45% |
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based
biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials including a Phase III
trial in head and neck cancers using REOLYSIN®, its
proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit:
www.oncolyticsbiotech.com.
This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements,
including the Company's belief as to the potential of REOLYSIN as a
cancer therapeutic; the Company's expectations as to the success of
its research and development programs in 2014 and beyond, the
Company's planned operations, the value of the additional patents
and intellectual property; the Company's expectations related to
the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the
design, timing, success of planned clinical trial programs; and
other statements related to anticipated developments in the
Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.